SF 0166

Drug Profile

SF 0166

Alternative Names: SF0166

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SciFluor Life Sciences
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 21 Dec 2017 SciFluor Life Sciences plans a phase II trial for Age-related macular degeneration
  • 18 Dec 2017 Adverse events and efficacy data from a phase I/II trial in Age-related macular degeneration released by SciFluor Life Sciences
  • 12 Dec 2017 SciFluor Life Sciences has patent protection for the use of SF 0166 topical ophthalmic solution in retinal diseases in Europe and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top